Nexalin Technology (NXL) Liabilities and Shareholders Equity (2021 - 2026)
Nexalin Technology (NXL) posted Liabilities and Shareholders Equity of $3.0 million for Q2 2026, down 18.69% on a QoQ basis from $3.7 million in Q1 2026, and down 54.23% year-over-year from $6.6 million in Q2 2025.
Analysis
Nexalin Technology (NXL) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Nexalin Technology has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $3.0 million in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 54.23% year-over-year to $3.0 million in Q2 2026; TTM through Jun 2026 was $16.5 million, a 13.11% decrease from a year earlier, with the FY2025 full-year figure at $4.6 million, up 9.77% from the prior year.
- Liabilities and Shareholders Equity was $3.0 million for Q2 2026 at Nexalin Technology, down from $3.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $8.4 million in Q3 2022, with the low at $1.6 million in Q2 2024.
- Average Liabilities and Shareholders Equity over 5 years is $4.7 million, with a median of $4.5 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 886.09% in 2022, then tumbled 69.8% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $7.4 million in 2022, then sank by 51.13% to $3.6 million in 2023, then climbed by 16.27% to $4.2 million in 2024, then advanced by 9.77% to $4.6 million in 2025, then tumbled by 35.19% to $3.0 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $3.0 million (Q2 2026), $3.7 million (Q1 2026), and $4.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.84 Bn | 174.23 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Intuitive Surgical | 128.02 Bn | 122.81 Bn | 1.96 Bn | 20.88 Bn |
| 3 | Medtronic | 117.28 Bn | 108.46 Bn | 6.34 Bn | 93.31 Bn |
| 4 | Stryker | 103.92 Bn | 100.44 Bn | 4.50 Bn | 47.93 Bn |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | 45.22 Bn |
| 6 | Edwards Lifesciences | 49.96 Bn | 45.70 Bn | 1.35 Bn | 13.87 Bn |
| 7 | Alcon | 32.86 Bn | 31.40 Bn | 1.68 Bn | 31.10 Bn |
| 8 | Dexcom | 32.25 Bn | 30.30 Bn | 830.00 Mn | 6.46 Bn |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Nexalin Technology | 3.42 Mn | 2.41 Mn | 8,897.00 | 3.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.69 Mn |
| Dec 31, 2025 | 4.64 Mn |
| Sep 30, 2025 | 5.13 Mn |
| Jun 30, 2025 | 6.56 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Sep 30, 2024 | 5.26 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 3.63 Mn |
| Sep 30, 2023 | 4.43 Mn |
| Jun 30, 2023 | 5.18 Mn |
| Mar 31, 2023 | 5.93 Mn |
| Dec 31, 2022 | 7.43 Mn |
| Sep 30, 2022 | 8.35 Mn |
| Dec 31, 2021 | 753,698.00 |